- Home
- PRPL vs TLSA Comparison
PRPL vs TLSA Comparison
Compare PRPL & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPL
- TLSA
- Stock Information
- Founded
- PRPL 2010
- TLSA 2013
- Country
- PRPL United States
- TLSA United Kingdom
- Employees
- PRPL N/A
- TLSA N/A
- Industry
- PRPL Home Furnishings
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- PRPL Consumer Discretionary
- TLSA Health Care
- Exchange
- PRPL Nasdaq
- TLSA Nasdaq
- Market Cap
- PRPL 96.8M
- TLSA 87.8M
- IPO Year
- PRPL N/A
- TLSA 2000
- Fundamental
- Price
- PRPL $0.77
- TLSA $1.08
- Analyst Decision
- PRPL Hold
- TLSA
- Analyst Count
- PRPL 2
- TLSA 0
- Target Price
- PRPL $1.25
- TLSA N/A
- AVG Volume (30 Days)
- PRPL 1.4M
- TLSA 1.0M
- Earning Date
- PRPL 03-13-2025
- TLSA 05-09-2025
- Dividend Yield
- PRPL N/A
- TLSA N/A
- EPS Growth
- PRPL N/A
- TLSA N/A
- EPS
- PRPL N/A
- TLSA N/A
- Revenue
- PRPL $487,877,000.00
- TLSA N/A
- Revenue This Year
- PRPL $3.96
- TLSA N/A
- Revenue Next Year
- PRPL $8.16
- TLSA N/A
- P/E Ratio
- PRPL N/A
- TLSA N/A
- Revenue Growth
- PRPL N/A
- TLSA N/A
- 52 Week Low
- PRPL $0.65
- TLSA $0.41
- 52 Week High
- PRPL $2.12
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- PRPL 41.00
- TLSA 44.39
- Support Level
- PRPL $0.79
- TLSA $0.96
- Resistance Level
- PRPL $0.90
- TLSA $1.30
- Average True Range (ATR)
- PRPL 0.08
- TLSA 0.17
- MACD
- PRPL 0.00
- TLSA -0.06
- Stochastic Oscillator
- PRPL 26.60
- TLSA 17.65
About PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms, and other products. It sells its products through online channels, traditional wholesale partners and third-party online retailers.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.